United States· US:73462-101_fd1c99c8-df20-4278-b963-603bb0c10715
COSELA
A trilaciclib product containing trilaciclib dihydrochloride, registered in United States by G1 Therapeutics, Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- TRILACICLIB DIHYDROCHLORIDE
- Manufacturer
- G1 Therapeutics, Inc.
- Country
- United States (US)
- ATC code
- V03AF12
- ATC class
- Trilaciclib
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1173462101011 VIAL, GLASS in 1 CARTON (73462-101-01) / 20 mL in 1 VIAL, GLASS
- ndc1173462-101-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under V03AF12
Trilaciclib, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cc6234b0-1f8e-49bc-9935-ab68adf7af8e GET /v1/drugs/cc6234b0-1f8e-49bc-9935-ab68adf7af8e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "300",
"substance": "TRILACICLIB DIHYDROCHLORIDE",
"productndc": "73462-101",
"dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/20mL",
"application_number": "NDA214200",
"marketing_category": "NDA"
}See everything about trilaciclib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.